GLP-1 Drugs Explored for Heart Disease and Diabetes in Kazakhstan
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs
Background
Cardiovascular diseases (CVDs), including Heart Failure, Type 2 Diabetes, and Arterial Hypertension, pose a significant health burden globally, with metabolic dysfunction often playing a central role. While glucagon-like peptide-1 (GLP-1) receptor agonists and dual incretin agonists have shown promise in improving metabolic control and cardiovascular outcomes, there is a knowledge gap regarding their efficacy and optimal implementation within the Kazakhstani population.
Study Design
Population
Kazakhstani patients with Heart Failure, Type 2 Diabetes, and Arterial Hypertension.
Intervention
GLP-1 receptor agonists and dual incretin agonists.
Outcome
Efficacy and optimal implementation of GLP-1 drugs for metabolic control and cardiovascular outcomes.